Clinical information
Diagnostic Utility:
It is based on the confirmation of the presence of IgG antibodies against the human immunodeficiency virus (HIV), using recombinant proteins and synthetic peptides of HIV-1 and HIV-2, and a synthetic peptide of HIV-1 group O (p17, sgp120, gp41, p31, p24, sgp105, and gp36) and is useful in:
- Confirmation of HIV-1 and HIV-2 antibodies in individuals with an active HIV infection or receiving HIV treatment.
Method:
Immunochromatographic strip assay.
Reference Values
Possible results are: Reactive (HIV-1/HIV-2), Non-reactive, and Indeterminate.
Diagnostic Algorithm:
Not applicable.
Turnaround Time:
Maximum 15 working days.
Specimen information
Sample: Serum and/or plasma
Tube: Aliquots of 1-5 mL, plasma tubes with citrate, EDTA or heparin as anticoagulant and/or serum tubes with and without gel separator.
Minimum necessary volume: 1 ml
Stability:
- At room temperature: ≤ 4 days
- In refrigeration 2-8 °C: ≤ 7 days
- Sample frozen at or below -20°C: 10 years
Transport instructions: Preferably at room temperature and/or refrigerated if they are total blood tubes and frozen if they are serum and/or plasma aliquots.
Reason for rejection: Sample very hemolyzed.
Administrative information
BST Code: 0114
Test Description: HIV-1/HIV-2, IgG Antibodies. Confirmation by Immunoblot.
Synonyms: anti-HIV-1/HIV-2
Section: Transfusion Safety Laboratory
BST Fee: Check the updated fees here.
Profiles:
N/A
References
- Inserts kits test INNO-LIA HIV I/II Score Insert.
Quality
BST holds ISO 9001, ISO 14001, and OSHAS 18001 quality certifications, as well as the European Excellence 500+ seal. BST is accredited by CAT, JACIE-FACT, FACT-NETCORD, and EFI, and complies with Good Manufacturing Practice (GMP) and Good Distribution Practice (GDP) guidelines.